{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:50:35Z","timestamp":1768553435864,"version":"3.49.0"},"posted":{"date-parts":[[2022,3,31]]},"group-title":"Epidemiology","reference-count":12,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The Danish authorities implemented a differential rollout of the COVID-19 vaccines where individuals at high risk of COVID-19 were prioritized. We describe the temporal uptake of COVID-19 vaccines and changing characteristics of vaccine recipients in Denmark.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    Using the Danish national health care registries, we identified all Danish residents \u22655 years of age who received at least one dose of a COVID-19 vaccine from December 27\n                    <jats:sup>th<\/jats:sup>\n                    , 2020, to January 29\n                    <jats:sup>th<\/jats:sup>\n                    , 2022. We charted the daily number of newly vaccinated individuals and the cumulative vaccine coverage over time, stratified by vaccine type, age groups, and vaccination priority groups. In addition, we described characteristics of vaccine recipients during 2-months-intervals and in vaccination priority groups.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    By January 29\n                    <jats:sup>th<\/jats:sup>\n                    , 2022, 86%, 84% and 63% of Danish residents \u22655 years had received a first, second, and third dose, respectively, of a COVID-19 vaccine, most commonly the BNT162b2 vaccine (84% of vaccinated individuals). Vaccine uptake ranged from 48% in 5-11-year-olds up to 98% in 65-74-year-olds. Individuals vaccinated before June 2021 were older (median age 61-70 years vs. 10-35 years in later periods) and had more comorbidities such as hypertension (22-28% vs. 0.77-2.8% in later periods), chronic lung disease (9.4-15% vs. 3.7-4.6% in later periods), and diabetes (9.3-12% vs. 0.91-2.4% in later periods).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The uptake of the COVID-19 vaccines is high in Denmark. We document substantial changes over time in characteristics of vaccine recipients which should be considered when designing and interpreting studies on the effectiveness and safety of COVID-19 vaccines.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2022.03.25.22272927","type":"posted-content","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:20:11Z","timestamp":1648772411000},"source":"Crossref","is-referenced-by-count":0,"title":["Changing characteristics over time of individuals receiving COVID-19 vaccines in Denmark: A population-based descriptive study of vaccine uptake"],"prefix":"10.64898","author":[{"given":"Mette","family":"Reilev","sequence":"first","affiliation":[]},{"given":"Morten","family":"Olesen","sequence":"additional","affiliation":[]},{"given":"Helene","family":"Kildegaard","sequence":"additional","affiliation":[]},{"given":"Henrik","family":"St\u00f8vring","sequence":"additional","affiliation":[]},{"given":"Jacob H.","family":"Andersen","sequence":"additional","affiliation":[]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[]},{"given":"Lars C.","family":"Lund","sequence":"additional","affiliation":[]},{"given":"Louise","family":"Ladebo","sequence":"additional","affiliation":[]},{"given":"Martin T.","family":"Ernst","sequence":"additional","affiliation":[]},{"given":"Per","family":"Damkier","sequence":"additional","affiliation":[]},{"given":"Peter B.","family":"Jensen","sequence":"additional","affiliation":[]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[]},{"given":"Lotte","family":"Rasmussen","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2022040210250839000_2022.03.25.22272927v1.1","first-page":"20155","article-title":"The Danish vaccination register","volume":"17","year":"2012","journal-title":"Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull"},{"key":"2022040210250839000_2022.03.25.22272927v1.2","doi-asserted-by":"crossref","unstructured":"Schmidt M , Schmidt SAJ , Sandegaard JL , et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 449.","DOI":"10.2147\/CLEP.S91125"},{"key":"2022040210250839000_2022.03.25.22272927v1.3","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw213"},{"key":"2022040210250839000_2022.03.25.22272927v1.4","first-page":"20667","article-title":"The Danish Microbiology Database (MiBa) 2010 to 2013","volume":"19","year":"2014","journal-title":"Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull"},{"key":"2022040210250839000_2022.03.25.22272927v1.5","doi-asserted-by":"crossref","unstructured":"Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021; n699.","DOI":"10.1136\/bmj.n699"},{"key":"2022040210250839000_2022.03.25.22272927v1.6","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399956"},{"key":"2022040210250839000_2022.03.25.22272927v1.7","doi-asserted-by":"crossref","first-page":"05027","DOI":"10.7189\/jogh.11.05027","article-title":"A rapid review of evidence on the determinants of and strategies for COVID-19 vaccine acceptance in low- and middle-income countries","volume":"11","year":"2021","journal-title":"J Glob Health"},{"key":"2022040210250839000_2022.03.25.22272927v1.8","unstructured":"The New York Times. Tracking Coronavirus Vaccinations Around the World 2021, https:\/\/www.nytimes.com\/interactive\/2021\/world\/covid-vaccinations-tracker.html (2022, accessed 21 January 2022)."},{"key":"2022040210250839000_2022.03.25.22272927v1.9","unstructured":"European Centre for Disease Prevention and Control. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU\/EEA, https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/COVID-19-vaccination-strategies-and-deployment-plans-Nov-2021.pdf (2021, accessed 21 January 2022)."},{"key":"2022040210250839000_2022.03.25.22272927v1.10","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm695152e2"},{"key":"2022040210250839000_2022.03.25.22272927v1.11","doi-asserted-by":"publisher","DOI":"10.1186\/s13584-021-00440-6"},{"key":"2022040210250839000_2022.03.25.22272927v1.12","unstructured":"Australia\u2019s COVID-19 vaccine national roll-out strategy, https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2021\/01\/covid-19-vaccination-australia-s-covid-19-vaccine-national-roll-out-strategy.pdf (accessed 21 January 2022)."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.03.25.22272927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:40:12Z","timestamp":1768488012000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.03.25.22272927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":12,"URL":"https:\/\/doi.org\/10.1101\/2022.03.25.22272927","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1177\/14034948221108246","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2022,3,31]]},"subtype":"preprint"}}